Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Ovarian Neoplasms 86Breast Neoplasms 68Triple Negative Breast Neoplasms 32Prostatic Neoplasms 32Fallopian Tube Neoplasms 25Neoplasms 23Neoplasm Metastasis 21Pancreatic Neoplasms 18Endometrial Neoplasms 18Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 11Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Sarcoma 9Recurrence 9Lung Neoplasms 9Fanconi Anemia, Complementation Group D1 9Squamous Cell Carcinoma of Head and Neck 8Glioma 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Colorectal Neoplasms 6Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Solid Tumors 4Osteosarcoma 4

Interventions

adavosertib 5durvalumab 3Paclitaxel 3olaparib 2ceralasertib 2Fluorouracil 2Carboplatin 2toripalimab 1sintilimab 1pembrolizumab 1factor IX, factor VII, factor X, prothrombin drug combination 1drug XX Z 1danvatirsen 1capivasertib 1Rifampin 1Pantoprazole 1Omeprazole 1Leucovorin 1Itraconazole 1Irinotecan 1Injections 1Gemcitabine 1Doxorubicin 1Cisplatin 1AZD0156 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Tumours × olaparib × Clear all
NCT02588105 2022-09-19

AToM

AstraZeneca

Phase 1 Completed
84 enrolled
Other solid neoplasm

Advanced Solid Tumours

NCT02430311 2019-07-31

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

AstraZeneca

Phase 1 Completed
36 enrolled 24 charts
Other solid neoplasm

Advanced Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡